Thermo Fisher Scientific Expands Investment in Bioprocessing with Breaking Ground on New Supply Center in Korea
Plan to build Bioprocess Supply Center and Clinical Service Facility on Yeongjongdo Island in 2022
Expected to meet the development demand for biopharmaceuticals such as vaccines in Korea, in the mid-to-long term
[Jan 25, 2022] Thermo Fisher Scientific, the world leader in serving life science, announced today that they will build the Bioprocess Supply Center in 2022 with an aim of providing a reliable supply of products and materials for the manufacturing of biopharmaceuticals, including vaccines, in Korea. In this way, Thermo Fisher plans to contribute to the stabilization of manufacturing by supplying the essential raw materials for biopharmaceutical manufacturing in Korea - both more efficiently and reliably.
With the rapid growth of the biopharmaceutical market including biosimilars, vaccines and cell and gene therapies, further amplified by COVID-19, a resilient supply for important raw materials that are necessary for the manufacturing has become more important than ever. Thermo Fisher, involved in various investment projects in Korea and throughout the Asia Pacific region, will build out a Bioprocess Supply Center and Clinical Service Facility on Yeongjongdo Island in 2022. Yeongjongdo Island is located near Songdo, Incheon a home to Korea’s leading bio companies, such as Samsung Biologics and Celltrion, forming a bio cluster for the country.
The investment expands on the $650 million dollar investment that Thermo Fisher announced last year for the expansion of its manufacturing capacity and supply of vital raw materials for biopharmaceuticals by end of 2022. It is currently in the process of expanding and building raw material sites around the world, including the US, Europe, and Asia.
The Bioprocess Supply Center will have a range of temperature-controlled facilities to store different products under rigorous quality control. The center is also slated to acquire the international certificate, ISO 13485, to provide a safe one-stop service to customers from product storage to delivery. The Clinical Service Facility that is to be expanded and relocated nearby will also offer exhaustive clinical development services, from purchasing comparators to sourcing, offering robust support to customers for the success of clinical trials.
Soojin Seok, Vice President and General Manager of Thermo Fisher Scientific Korea, said, “The Bioprocess Supply Center and the Clinical Service Facility that are to be completed in 2022 will support the production of a diverse range of biopharmaceuticals, including COVID-19 vaccines, and contribute to the advancement of Korea’s biopharmaceutical industry.”
Thermo Fisher has established a number of experience and innovation centers in Korea to showcase the latest scientific technologies to its customers. Last July, the Bioprocess Design Center in the Songdo Bio Cluster launched with an aim of effectively supporting the biomanufacturing companies in Korea. Additionally, the Customer Experience Center in Suseo, Gangnam, Seoul where you can implement the largest number of scientific applications in the nation, is also expanding its space for cell therapy products, special diagnostics, and environmental and materials industries, while making hefty investments to deliver the latest scientific technology to customers in Korea.
Moreover, the Thermo Fisher NanoPort Customer Innovation Center in Giheung, Yongin supports the initiative to maximize customer productivity in the semiconductor and science industries, while the Pipette Calibration Center in the Seoul Suseo Office provides sophisticated technical support services in the research and test sectors, including bio, medicine, and food.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc., headquartered in Waltham, Massachusetts, US, is the world leader in serving science, with annual revenue of approximately $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team of more than 100,000 colleagues delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com.